Human IgG3 displays the strongest effector functions of all IgG subclasses but has a short half-life for unresolved reasons. Here we show that IgG3 binds to IgG-salvage receptor (FcRn), but that FcRn-mediated transport and rescue of IgG3 is inhibited in the presence of IgG1 due to intracellular competition between IgG1 and IgG3. We reveal that this occurs because of a single amino acid difference at position 435, where IgG3 has an arginine instead of the histidine found in all other IgG subclasses. While the presence of R435 in IgG increases binding to FcRn at neutral pH, it decreases binding at acidic pH, affecting the rescue effi ciency -but only in the presence of H435 -IgG. Importantly, we show that in humans the half-life of the H435-containing IgG3 allotype is comparable to IgG1. H435 -IgG3 also gave enhanced protection against a pneumococcal challenge in mice, demonstrating H435 -IgG3 to be a candidate for monoclonal antibody therapies.
H uman IgG3 activates complement and Fc γ R-mediated functions more eff ectively than any other subclass, followed by IgG1, IgG2 and IgG4, respectively, making it an ideal candidate for immunotherapy 1 -4 . However the short half-life of one week for IgG3, compared with three weeks for the other subclasses, currently makes IgG1 the therapeutic subclass of choice 4, 5 .
Th e exceptionally long half-life of IgG is mediated by a single receptor, the neonatal Fc receptor for IgG (FcRn) 6, 7 . FcRn is a heterodimer consisting of a unique MHC class-I like α -chain, associated with β 2M. Because its affi nity for IgG is negligible at physiological pH ( ~ 7.4), FcRn binds to IgG only aft er pinocytosis within early endosomes (pH ≤ 6.5) 8, 9 . FcRn -IgG complexes are then routed away from the lysosomal pathway 10 -13 , and either cycled back to the cell surface or transported to the opposite side of the cell. Th e vesicles fuse with the plasma membrane, returning the pH to ~ 7.4, and releasing IgG 14 -16 . Besides IgG transport, FcRn enhances IgG-mediated phagocytosis as well as antigen presentation by both MHC class I and II 16 -19 , and has a key role in rescuing albumin from lysosomal degradation 20 .
Two theoretical explanations for the reduced half-life of IgG3 have been suggested. First, the long hinge region of IgG3 might make it more prone to proteolytic degradation 4 . Second, the recycling of IgG3 by FcRn may be less effi cient because of an amino acid diff erence at position 435 -a key contact residue with FcRn and, in IgG1, IgG2 and IgG4, important for the pH-dependent formation of IgG -FcRn complexes through histidine protonation around pH ≤ 6.5 (refs 8, 9, 21, 22) . IgG3 contains an arginine in this position (R435), and although both residues classify as positively charged, arginines, unlike histidines, do not deprotonate at neutral pH, theoretically resulting in IgG3 binding to FcRn being less pHdependent, leading to shortened half-life as described for various mutated IgG variants with increased affi nity to FcRn at neutral pH (refs 8, 23) . Previous experimental work indeed pointed to the involvement of R435, as human IgG1 -Fc and scFv -IgG1 -Fc fragments bearing R435 showed reduced half-life in wild-type mice 24, 25 . Human H435R -IgG4 variant was also reported to display an altered binding to rat FcRn 8 . However, species-incompatible FcRn were used in these studies; the exceptional long hinge of IgG3 was not present; and the underlying mechanisms were not explored 4,8,24 -27 .
Here we investigate the diff erence in FcRn-mediated transport and rescue of IgG1 and IgG3. Using human in vitro and in vivo models, we observed -unexpectedly -that both IgG1 and IgG3 show pH-dependent binding to FcRn, and that FcRn can transport IgG3 as effi ciently as IgG1. However, when both IgG1 and IgG3 are present, IgG1 inhibits FcRn-mediated IgG3 transport, leading to degradation of IgG3. Our data provide strong evidence that the presence of an arginine at position 435 in IgG3 is suffi cient to explain its high rate of catabolism observed in vivo . Importantly, we show that the half-life of the H435-containing IgG3 allotype is comparable to IgG1 in humans. Using a mouse model for pneumococcal pneumonia, we provide a proof of concept that IgG3 -R435H can be utilized for IgG-based immunotherapies aiming at maximizing eff ector functions.
Results

IgG1 interferes with IgG3 transport .
To study FcRn-mediated functions, we developed an in vitro transport model by transducing the FcRn-negative human cell line A375 with the human FcRn α -chain (A375 -FcRn). Th e wild-type A375 did not transport IgG using intravenous immunoglobulin (IVIg), a polyclonal mixture of all human IgG subclasses ( Fig. 1a ) . However, active transport was observed in A375 -FcRn cells in medium buff ered at pH 7.4. We found IgG transport in A375 -FcRn to be similar to that observed across placental syncytiotrophoblast derived JAR cells expressing endogenous FcRn ( Fig. 1b ) . From IVIg, A375 -FcRn cells transported IgG3 less eff ectively than IgG1, but JAR transported relatively equal amounts of both IgG1 and IgG3 ( Fig. 1a,b ) . The data represent mean and standard deviation from three independent experiments. Statistical comparison was performed by one-way ANOVA followed by Tukey ' s multiple comparison test in ( a , b ), and transport of IgG3, in the presence of IgG1, was compared with transport of IgG3 alone by two-tailed t -test in ( c , d ). * P ≤ 0.05; * * P ≤ 0.01; * * * P ≤ 0.001.
When IVIg was pre-incubated with Z-domains of protein A, a selective competitive inhibitor of FcRn binding to IgG1, IgG2 and IgG4 (refs 28, 29) , transport of IgG1 by JAR and A375 -FcRn cells was reduced to levels approaching those found in parental A375-WT and for non-specifi c horseradish peroxidase (HRP) transport and ( Fig. 1 ) , indicating IgG1 transport to be FcRn-dependent in both cell types. Remarkably, IgG3 transport was signifi cantly increased in both JAR and A375 -FcRn cells by the addition of Z-domains ( Fig. 1a,b ) , suggesting that active transport of the other IgG subclasses interfered with IgG3 transport.
We therefore studied the eff ect of IgG1 on the FcRn-mediated transport of IgG3 using purifi ed antibodies. Indeed, IgG3 alone was transported equally well as IgG1, and the transport of IgG3 was inhibited by adding IgG1 to A375 -FcRn ( Fig. 1c ) or JAR cells ( Fig. 1d ) . As the percentage of IgG1 or IgG3 transport was unaff ected by the initial IgG concentration (measured over a range from 1 to 350 μ g ml − 1 ; Fig. 1e ) the observed inhibition of IgG3 transport by IgG1 (at concentrations of 50 -100 μ g ml − 1 ) cannot be owing to FcRn saturation. Th e pH in the extracelluar medium was set at pH 7.4, suggesting the inhibition to takes place in intracellular compartments.
IgG1 and IgG3 compete for binding to FcRn and transport . Ober et al. demonstrated that, during sorting, the unbound FcRn molecules are routed away from the sorting endosomes 15 . Th is might explain the observed competition between IgG1 and IgG3 for FcRn binding and transport, because the number of FcRn molecules in intracellular compartments can also become limited under nonsaturating conditions. Indeed, we show that when the IgG3 concentration was kept constant at 10 μ g ml − 1 , IgG1 concentrations as low as 1 ng ml − 1 signifi cantly reduced IgG3 transport ( Fig. 2a ) . When IgG1 and IgG3 were mixed in equal amounts, the relative IgG3 transport was signifi cantly reduced, compared with transport of IgG3 alone at high concentrations, but was unaff ected at IgG concentrations of 10 ng ml − 1 / subclass, when ~ 4 % of 1.25 μ m sorting endosomes 15 would be expected to contain IgG ( Fig. 2b ) . Remarkably, this concentration of IgG1 (10 ng ml − 1 ) signifi cantly inhibited a 1,000-fold excess of IgG3 (10 μ g ml − 1 , Fig. 2a ) . Similarly, soluble IgG1 was more effi cient than IgG3 in inhibiting binding of soluble human FcRn (shFcRn) to IgG3-immobilized biosensor chips ( Fig. 2c,d ).
R435 in IgG interferes with binding to FcRn . When the diff erences in position 435 between IgG1 (Histidine) and IgG3 (Arginine) were modelled into the existing crystal structure 21 , it was clear that the longer side chain of arginine may potentially disrupt the tight fi t of IgG in the FcRn-binding pocket ( Fig. 3a,b ) . However, theoretically it may also convey a more favourable charge at pH 7.4, at which the net charge of histidine is neutral but arginine is positive 22 . IgG3 did indeed bind to shFcRn signifi cantly better at pH 7.4, but IgG1 bound better at pH 6.0 as measured by ELISA ( Supplementary Fig.  S1 ) and by surface plasmon resonance (SPR) ( Fig. 3c,d ). We subsequently mutated IgG1 to include the IgG3-derived arginine residue and vice versa (IgG1 -H435R and IgG3 -R435H, respectively). Th ese mutations resulted in the loss (IgG1 -H435R) or gain (IgG3 -R435H) of protein A binding ( Supplementary Fig. S1 ).
Using shFcRn-coupled biosensor chips in SPR experiments, we noted that IgG1 -H435R showed improved binding to FcRn at pH 7.4 compared with WT IgG1, but reduced binding affi nity at acidic pH. Likewise, binding of IgG3 -R435H was reduced at pH 7.4, but improved at acidic pH compared with WT IgG3 ( Fig. 3c,d ) . Th e relative binding of both IgG subclasses and variants was however very weak at pH 7.4, but increased steadily as the pH decreased, showing that shFcRn binding remained pH-dependent for all variants.
Th e H435-containing IgG variants bound shFcRn with similar calculated affi nities at pH 6.0 according to the bivalent ligand-binding model. However, IgG3 and IgG1 -H435R had calculated kinetic dissociation constant (K D s) that were, respectively, two times and ~ 50 % higher than WT IgG1 ( Supplementary Fig. S2 ; Supplementary Table S1 ). Similar results were found using the heterogeneous ligand-binding model and by repeating the experiments with a reversed set-up, using IgG-coupled biosensor chips and the steadystate affi nity model 30 : shFcRn bound the strongest to IgG1-coupled chips at pH 6.0 whereas IgG1 -H435R showed reduced binding. Th e affi nity of shFcRn was improved for IgG3 -R435H compared with IgG3 that showed the weakest affi nity of all variants ( Fig. 4 ) .
Th e inhibition of IgG3 transport by IgG1 is due to R435
. In agreement with the retained pH-dependent FcRn-binding, the presence of histidine or arginine at position 435 did not infl uence the transport effi ciency of either subclass when transported individually in A375 -FcRn cells ( Fig. 5a ). When the amino acid at position 435 was mutated to an alanine, binding to protein A and shFcRn ( Supplementary Fig. S1 ) as well as FcRn-dependent transport ( Fig. 5a ), was almost entirely abrogated both for IgG1 and IgG3. When mixed, IgG1 -H435A did not inhibit transport of IgG3 ( Fig. 5b ) , indicating that binding of IgG1 to FcRn was required for the observed inhibition of IgG3 transport. Importantly, IgG1 -H435R ( Fig. 5a ) was also unable to inhibit IgG3 transport ( Fig. 5b ) , indicating the arginine / histidine diff erence between IgG3 and IgG1 to be important for IgG1-mediated inhibition of IgG3 transport. In line with this, transport of IgG3 -R435H was unaff ected by the presence of any IgG1 variant ( Fig. 5c ) . Remarkably, IgG3 -R435H inhibited transport of IgG1 -H435R ( Fig. 5c ) to a similar extent as IgG1-WT inhibited transport of IgG3-WT ( Fig. 5b ) . Th ese results demonstrate that IgG -R435 can be transported by FcRn through cells, but that binding to, and transport by, FcRn is inhibited in the presence of H435-containing IgG.
Competition for FcRn leads to degradation of IgG3 in vitro . We next tested whether the reduced IgG3 transport in the presence of IgG1 was refl ected in enhanced degradation during apical to basolateral transport. We therefore measured the recovery of diff erent IgG variants from the apical and basolateral compartments ( Fig. 6a ) . Up to 95 % of IgG1 or IgG3 could be accounted for when transported alone. When mixed with IgG3, IgG1 recovery was unaff ected, but only 60 % of the initial amount of IgG3 was detected. However, when WT IgG1 and IgG3 -R435H were mixed, recovery of both was ~ 95 % ( Fig. 6a ) , indicating that the decreased transport and enhanced loss of IgG3 in the presence of IgG1 was solely due to the arginine at position 435.
IgG3 with H435 has an enhanced half-life in humans . Th e IgG3 G3m( s , t ) allotype ( Supplementary Fig. S3 ) contains a histidine at position 435, and can therefore be used to investigate the in vivo eff ect of the mutation. Although not commonly found in native Europeans, we found detectable levels in IVIg ( Supplementary  Fig. S4 ). 31 -34 We therefore investigated whether R435 can also cause the fast clearance of IgG3 in vivo , by analysing the serum persistence of this IgG3 allotype in sera of IVIg-treated X-linked agammaglobulinemic patients. Compared with the amounts found in the IVIg preparation itself, the amount of IgG1 and IgG2 relative to total IgG was unchanged in these patients four weeks aft er the last infusion of IVIg ( Fig. 6b ) . As expected, the total serum IgG3 level, consisting mostly of R435 containing G3m(b) and G3m(g) allotypes in Europe 31, 32 ( Supplementary Fig. S3 ), was signifi cantly lowered, but signifi cantly increased for the H435-containing IgG3 allotype G3m( s , t ) ( Fig. 6b ) . Th us, also in natural variants of IgG3, the presence of a histidine or an arginine at position 435 determines the catabolic rate in vivo .
Enhanced eff ector functions of H435 containing IgG3 in vivo . IgG3 binds C1q and activates Fc γ R more potently than any of the other IgG subclasses, but its therapeutic application has not yet been considered a viable option because of its short half-life 4, 35, 36 . We therefore compared the potential of the recombinant V-gene-matched IgG1, IgG3, IgG1 -H435R and IgG3 -R435H (directed against Streptococcus pneumoniae serotype 6) 17,37 to stimulate Fc γ R-mediated phagocytosis and mediate protection against pneumococcal pneumonia and bacteremia. IgG3 mediated more phagocytosis than IgG1, and neither isoallotypic alteration (IgG1 H435R / IgG3 R435H) significantly changed the capacity of the antibodies to mediate phagocytosis of pneumococci ( Supplementary Fig. S5 ). We then passively immunized outbred NMRI mice 48 h before measuring the level of the human antibodies and intranasal challenge with virulent pneumococci. Th e serum persistence of all four IgG were measured before challenge that were found to be lower for IgG3 and IgG1 -H435R than for IgG1 and IgG3 -R435H ( Fig. 7a ) . Bacteremia and pneumonia were determined 24 h later 37 . IgG1 and IgG3 -R435H completely protected against bacteremia, whereas IgG3-and IgG1 -H435R-treated mice were partly protected ( Fig. 7b ) . IgG3 -R435H demonstrated a signifi cantly better protection against pneumonia than IgG1 and IgG3, whereas IgG1 -H435R was not protective ( Fig. 7c ) . A complete clearance for a large fraction of the mice was only observed in the IgG3 -R435H-treated group ( Fig. 7b,c ) . Th e statistical analysis of the data in Figure 7b is displayed in Table 1 . Collectively, these data reveal that the short half-life described for human IgG3 is due to the arginine in position 435, that can be overcome by introducing an histidine present in this position in the G3m( s , t ) allotypes and other IgG subclasses. Th e in vivo application of H435 -IgG3 combines the properties of long half-life and strong eff ector functions that surpasses that of human IgG1. 
Discussion
In this study, we investigated the binding of IgG3 to FcRn, which, although slightly lower and less pH-dependent, was surprisingly similar to IgG1. In agreement with this, we found FcRn-mediated transport of purifi ed IgG3 to be comparable to that of IgG1. Th ese fi ndings fail to explain the short half-life of IgG3 in humans. However, we found an unexpected inhibition of IgG3 transport in the presence of other IgG subclasses. Th is was because of intracellular competition for FcRn-mediated transport owing to a single amino acid diff erence in position 435 between IgG3(arginine) and the other IgG subclasses (histidine), which explains the shorter plasma half-life of IgG3. Mutating this arginine in IgG3 to histidine abrogated the inhibition by IgG1, without aff ecting the superior eff ector functions of IgG3. FcRn-mediated transport and degradation were studied in hFcRntransfected human A375 cells and in the naturally FcRn-expressing human choriocarcinoma cellline JAR. Th e transport rates of purifi ed IgG1 and IgG3 were similar for various IgG sources. However, in both cell types, the transport of IgG3 was inhibited by addition of IgG1. Th is inhibition was observed for myeloma IgG1 combined with IgG3 purifi ed from Intramuscular Ig (IMIg), for V-gene-matched recom- per subclass). However, when the IgG1 and IgG3 were mixed in equal amounts, ~ 65 % of the initial IgG3 could be detected, suggesting IgG3 was degraded in the presence of IgG1. IgG1 recovery was similar to that found when no IgG3 was present. IgG3 -R435H was not degraded in the presence of IgG1 as about 95 % could be detected after 24 h, similarly to IgG3 alone. The data represent mean and standard deviation from three independent experiments. ( b ) The relative concentration of IgG subclasses and the histidine-435 containing IgG3 allotype G3m( s , t ) in sera from agammaglobulinemic patients four weeks after their last treatment with IVIg compared with IgG subclass and G3m( s , t ) levels found in the corresponding IVIg preparation. Data represent the average plus standard deviation calculated from at least three independent IgG subclass and allotype measurements performed on serum from three patients in ( b ). Statistical comparison was performed by one-way ANOVA followed by Tukey ' s multiple comparison test in ( b ). * P ≤ 0.05; * * * P ≤ 0.001. For simplicity, signifi cant differences are only displayed for IgG1 compared with all subclasses, and between IgG3 total and G3m( s , t ) levels in ( b ).
FcRn molecules on parallel membranes binding to one IgG molecule 21, 39 . If IgG in transit goes through multiple checkpoints in tubule-tethered recycling-endosomes 15 , then competition between IgG3 and IgG1 may occur sequentially. Diff erences in on-rates were the most prominent fi nding from the interaction kinetics studies, and this may at least partly explain the ability of low concentrations of IgG1 to inhibit IgG3-transport. Our fi ndings that reduced IgG3 transport in the presence of IgG1 coincides with enhanced IgG3 degradation, support the hypothesis that this eff ect occurs aft er uptake and within developing lyso-and / or sorting endosomes. We found that mutating position 435 in IgG to an alanine-reduced transport almost to background levels and that IgG1 -H435A was unable to inhibit FcRn-mediated IgG3 transport. Transportinhibition of IgG3 by IgG1 was completely reversed by swapping the amino acids normally present in IgG1 and IgG3 at position 435 (resulting in IgG1 -H435R and IgG3 -R435H). Th is strongly indicated that human IgG1 is more adept at FcRn-mediated transport than IgG3, solely because of the R present at position 435 in IgG3. R435-containing IgG also bound shFcRn with a slightly lower affi nity than H435-containing IgGs, and soluble IgG1 was better than IgG3 in inhibiting binding of shFcRn to solid-phase immobilized IgG3. Th is amino acid diff erence was found to aff ect IgG3 binding to FcRn in two ways -likely through reduced sensitivity to deprotonation resulting in enhanced binding at pH 7.4, and through steric hindrance, causing decreased binding at pH 6.0, suggesting IgG3 to have a decreased competitiveness for pH-dependent FcRn binding and release, and thus for the overall transport.
To study whether our in vitro observations also apply in vivo , we analysed sera from agammaglobulinemic patients who receive regular IVIg replacement therapy that contain both R435-and H435-bearing IgG3 allotypes. We measured the relative IgG subclasses, and IgG3 allotype levels found in IVIg and sera, four weeks aft er the previous IVIg dose was given. In agreement with our in vitro fi ndings, we found that these sera were enriched for the H435-containing IgG3 allotypes compared with total IgG3, demonstrating that the R435 is also responsible for the lack of competitive FcRn-mediated rescue and short half-life of IgG3 in humans. In accordance with this, we found the serum persistence of IgG1 and IgG3 R435H to be higher than that of IgG3 and IgG1 H435R in outbred NMRI mice. Furthermore, these fi ndings show that the longer hinge of IgG3 does not lead to increased proteolytic degradation, which has been postulated to contribute to the lower half-life of IgG3 (ref. 4) .
IgG3 binds Fc γ RIII and C1q with higher affi nity than IgG1 and is capable of mediating considerably stronger eff ector functions, such as antibody-dependent cellular cytotoxicity, respiratory burst phagocytosis 1,36,40 -42 , and complement-dependent cytotoxicity towards tumour cells 3, 43 . Th is suggests IgG3 containing H435 to be a more eff ective candidate for in vivo immunotherapies. In an in vivo model of IgG-mediated protection against pneumococcal sepsis and bacteremia WT IgG3 gave comparable protection against pneumonia as IgG1. However, IgG3 -R435H protected mice signifi cantly better than either IgG1 or IgG3 against pneumococcal pneumonia, correlating both with its enhanced eff ector functions and half-life in mice, and confi rming its therapeutic potential 24 . Table 1 .
In summary, IgG3 is known for both its superior eff ector functions compared with IgG1 -the most commonly used isotype used for immunotherapy -but also for its short in vivo half-life 4, 5, 35, 36 . We now show that FcRn can in fact rescue and transcytose IgG3 as effi ciently as IgG1, but not in the presence of the other IgG subclasses.
Our data support a model where IgG3 loses competition for FcRn binding and routing away from the lysosomal pathway, explaining its high catabolism in vivo . We demonstrate that this can be resolved by replacing the R435 with a histidine, as is the case in a rare natural variant. Th e epitope comprising the H435 in G3m( s , t ) is an isoallotype that is found in all other IgG subclasses, and its detectable presence in IVIg has not been documented to cause adverse reactions in patients. Th e extended half-life of the IgG3 -R435H variant has important implications for current and future antibody-based therapies aimed at achieving maximal eff ector functions.
Methods
Cell culture . Human choriocarcinoma cells (JAR, ATCC, VA) were grown in IMDM medium ( Cambrex ) and melanoma cells (A375, FcRn − β 2m + , ATCC) in RPMI 1,640 medium ( Invitrogen / Gibco ), both supplemented with l-glutamin (300 μ g ml − 1 , Invitrogen ), penicillin (100 U ml − 1 , PAA Laboratories ), streptomycin (100 μ g ml − 1 , PAA ) and 10 % foetal calf serum ( FCS ).
A375 -FcRn
. Human FcRn messenger RNA was amplifi ed aft er fi rst strand cDNA synthesis by PCR using the forward 5 ′ -GGATCCACCATGGGGGTCCCGCGGCC TCAGC-3 ′ and reverse 5 ′ -GAATTCTCAGGCGGTGGCTGGAATCAC-3 ′ primers and ligated into pGEM-T (Promega, Madison, WI, USA). Th e Bam HI -Eco RI fragment was subcloned into the pMX-puro vector ( DNAX ) and transfected together with a packaging vector into 293T-cells 44 . Supernatants were used to transduce A375 cells 45 . Expression of FcRn was confi rmed by quantitative RT -PCR 17 .
IgG . IVIg was obtained from Sanquin . Pooled myeloma IgG1 was purifi ed from three multiple myeloma patients by serum protein precipitation and depletion of other subclasses by sephadex-bound anti-subclass Ig. IgG3 was obtained from IMIg ( Sanquin ) aft er depleting other IgG with protein A.
Recombinant IgG1, IgG3 and IgG1 -H435A have been described before 17, 37 . Recombinant IgG were produced in 293 Freestyle cells ( Invitrogen ) according to the manufacturer ' s instructions, and purifi ed using HiTrap protein A (for H435-containing IgGs) or protein G using the Acta Prime Plus system ( GE Healthcare ). IgG1 -H435R, IgG3 -R435A and IgG3 -R435H were generated using the Quickchange Site-directed-mutagenesis kit ( Stratagene ) with the following and reverse complementary oligonucleotide primers:
IgG1 -H435R:
GAGGCTCTGCACAACC G CTACACGCAGAAGAGCC IgG3-R435A: GAGGCTCTGCACAAC GC CTACACGCAGAAGAGCC IgG3 -R435H: GAGGCTCTGCACAACC A CTACACGCAGAAGAGCC All mutations were confi rmed by sequencing before expression. Th e endotoxin levels of the various batches was tested and confi rmed to be very low or absent by measuring IL-6 production of monocyte-derived immature DC, as described in ref. 46 .
Z domain . Th e gene encoding the Z-domain was amplifi ed by PCR from the vector pTh io-His-ZZ 47 using 5 ′ -GGATCCGTAGACAACAAATTCAAC-3 ′ (forward) and 5 ′ -CTGCAGTTATTTCGGCGCCTGAGCATC-3 ′ (reverse), and cloned into pGEM-T ( Promega ). Th e Bam HI -Not I fragment was cloned into the pGEX 6.2 expression vector and expressed in Escherichia coli . Th e GST tag was removed using PreScision protease ( GE healthcare ) and the Z-domain eluted off the glutathione sepharose 4B column ( GE healthcare ) by gravity fl ow and dialysed against PBS.
IgG transcytosis . 12 mm polycarbonate Transwell fi lters (0.4 μ m pore size, Costar / Corning ) were inoculated with 5 × 10 5 cells, grown overnight to confl uence, washed with PBS and medium replaced with fresh 1.5 ml medium basolaterally and 0.5 ml apically (IMDM at pH 7.4 with supplements as stated above). Mixtures of IgG contained 125 pg ml − 1 streptavidin-HRP ( Sanquin ) to assess background transport. Apical to basolateral transport was calculated according to ([IgG] basolateral × 1.5 ml) / ([IgG] input × 0.5 ml) × 100 % . All experiments were performed in triplicate.
Surface plasmon resonance assays . All experiments were performed using a Biacore 3000 instrument , CM5 biosensor chips and amine coupling as described by the manufacturer ( GE Healthcare ). Injections were done using phosphate buff er (67 mM phosphate buff er, 0.15 M NaCl, 0.05 % Tween20) at pH 6.0. Kinetic evaluations were performed using immobilized shFcRn -GST ( ~ 1,000 RU) 48, 49 , and IgG variants (2 -500 nM) injected. Alternatively, IgG was immobilized ( ~ 1,500 RU) and shFcRn injected (7 -4,000 nM). For the competitive SPR assay, chips were coupled with IgG ( ~ 1,300 RU) and shFcRn (100 nM) was injected alone or together with serial dilutions of IgG1 or IgG3. Binding at diff erent pH was done in a phosphate buff er with 500 nM IgG injected over immobilized shFcRn ( ~ 2.000 RU). All experiments took place at 20 -60 μ l min − 1 , 25 ° C, and HBS-P buff er ( GE Healthcare ) at pH 7.4 was used for regeneration. Binding analyses were performed using the BIAevaluation wizard soft ware 4.1. Fig. S4 ) for capture. Mouse-anti-IgG-HRP ( Southern Biotech ) was used for detection in all assays except the G3m( s , t ) ELISA where mouse anti-IgG3-HRP ( MH163-1 , Sanquin) was used. Concentration was read of standard curves made using the same IgG preparations used for transport or to treat patients.
Passive protection . Th e pneumococcal infection model has been described before 37, 50 . In brief, outbred NMRI mice ( Taconic ) were passively immunized intraperitoneally with 3 μ g of recombinant IgG (diluted in 200 μ l PBS) or saline only, 48 h before challenge with a virulent pneumococcal strain of serotype 6A. Mice were anesthetized and challenged intranasally with 2 × 10 7 CFU pneumococci in 50 μ l sterile 0.9 % saline. Twenty-four hours aft er challenge, the mice were killed and bacterial load evaluated by colony counting as described in refs 37, 50. All in vivo studies complied with the Animal Experimental Committee of Iceland According to the Act on Animal Welfare no 15 / 1994.
Statistical analysis and data sets . All data represent the mean and standard deviation of at least three independent experiments. All transcytosis assays consisted of three replicates. GraphPad Prism version 4.00 for Windows ( GraphPad Soft ware ) was used for all statistical analysis. Signifi cance was set at P ≤ 0.05, and the level of signifi cance is indicated on all fi gures as * P ≤ 0.05; * * P ≤ 0.01; * * * P ≤ 0.001. 
